Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03298672 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics Study of NDX-1017
A Phase 1 study, sponsored by LeonaBio.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT03298672 is a Phase 1 study that has completed, run by LeonaBio. The registered enrollment target is 88 participants.
The verdict
NCT03298672, a Phase 1 study, has completed, sponsored by LeonaBio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of NDX-1017 in healthy young and elderly subjects, and elderly subjects with amnestic mild cognitive impairment (MCI), Alzheimer's disease (mild, mild-to-moderate, or moderate), or mixed dementia with Alzheimer's and vascular components (mild, mild-to-moderate, or moderate).
Interventions
- DRUG Placebo
- DRUG NDX-1017
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2017-10-09 |
| Est. Completion | 2019-09-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03298672
The ClinicalTrials.gov registry entry for NCT03298672 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LeonaBio, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03298672 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03298672 about?
NCT03298672 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics Study of NDX-1017". This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of NDX-1017 in healthy young and elderly subjects, and elderly subjects with amnestic mild cognitive impairment (MCI), Alz...
What is the current status of trial NCT03298672?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2017-10-09. Estimated completion is 2019-09-05.
What interventions are being tested in trial NCT03298672?
The interventions under investigation include: Placebo (DRUG), NDX-1017 (DRUG).
Who is sponsoring clinical trial NCT03298672?
This trial is sponsored by LeonaBio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.